CAS 1929519-13-0

TAK-041

CAS : 1929519-13-0

Formule : C₁₈H₁₅F₃N₄O₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 392.3319

Ref: IN-DA0200XH

(S)-2-(4-Oxobenzo[D][1,2,3]Triazin-3(4H)-Yl)-N-(1-(4-(Trifluoromethoxy)Phenyl)Ethyl)Acetamide

CAS : 1929519-13-0

(S)-2-(4-Oxobenzo[D][1,2,3]Triazin-3(4H)-Yl)-N-(1-(4-(Trifluoromethoxy)Phenyl)Ethyl)Acetamide

Degré de pureté : 98%

Masse moléculaire : 392.33g/mol

Ref: 54-PC108475

TAK-041

CAS : 1929519-13-0

TAK-041

Degré de pureté : ≥98%

Masse moléculaire : 392.33g/mol

Ref: 54-BUP07978

TAK-041

CAS : 1929519-13-0

TAK-041 (NBI-1065846) is a potent and selective GPR139 agonist.

Formule : C₁₈H₁₅F₃N₄O₃

Degré de pureté : 99.95%

Couleur et forme : Solid

Masse moléculaire : 392.33

Ref: TM-T9317

TAK-041

CAS : 1929519-13-0

TAK-041 is an analog of a protein that acts as an anticancer agent by inhibiting cyclin-dependent kinases (CDKs). This inhibitor has been shown to be effective against various types of cancer cells, including those derived from human urine and Chinese hamster ovary cells. TAK-041 induces apoptosis in cancer cells by inhibiting the activity of CDKs, which are involved in cell cycle regulation. The inhibition of these kinases leads to cell cycle arrest and ultimately cell death. TAK-041 is a promising candidate for the development of new anticancer drugs and may have potential as a targeted therapy for a variety of tumors.

Formule : C₁₈H₁₅F₃N₄O₃

Degré de pureté : Min. 95%

Masse moléculaire : 392.3 g/mol

Ref: 3D-ECD51913